Precision Biosciences (DTIL) Net Equity Issued and Repurchased (2021 - 2023)

Precision Biosciences (DTIL) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $2.8 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to $2.8 million; the TTM figure through Dec 2023 stood at $5.0 million (down 89.9% YoY), while the FY2023 annual figure was $5.0 million, down 89.9% from the prior year.
• Net Equity Issued and Repurchased advanced to $2.8 million in Q4 2023 per DTIL's latest filing, from -$138000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $47.9 million in Q2 2022 and bottomed at -$190000.0 in Q3 2022.
• Historically, Net Equity Issued and Repurchased has averaged $7.8 million across 3 years, with a median of $1.9 million in 2023.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 102.26% — and 2023, when it increased 27.37%.
• Precision Biosciences' Net Equity Issued and Repurchased stood at $7.3 million in 2021, then plunged by 102.59% to -$190000.0 in 2022, then surged by 1587.89% to $2.8 million in 2023.
• Business Quant data shows DTIL's Net Equity Issued and Repurchased at $2.8 million in Q4 2023, -$138000.0 in Q3 2023, and $1.9 million in Q2 2023.